Quarterly report pursuant to Section 13 or 15(d)

Licenses Acquired - Additional Information (Detail)

v3.20.2
Licenses Acquired - Additional Information (Detail)
$ / shares in Units, € in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2020
USD ($)
Sep. 30, 2020
EUR (€)
May 06, 2020
USD ($)
shares
Sep. 30, 2020
USD ($)
$ / shares
Sep. 30, 2020
EUR (€)
Sep. 30, 2019
USD ($)
Sep. 30, 2020
USD ($)
$ / shares
Sep. 30, 2020
EUR (€)
Sep. 30, 2019
USD ($)
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Total consideration             $ 1,000,000   $ 2,400,000
Stock Issued During Period, Value, Issued for Services       $ 18,000     18,000    
Product revenue, net       9,447,000   $ 9,492,000 30,808,000   $ 23,816,000
Licensing Agreements [Member] | SIRION Technology License [Member]                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Payment of Upfront Fees       $ 100,000 € 0.1   $ 100,000 € 0.1  
Licensing Agreements [Member] | SIRION Technology License [Member] | Additional Milestone Payments [Member]                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Revenue Recognition Milestone Method Payments Due $ 4,100,000 € 3.5              
Licensing Agreements [Member] | SIRION Technology License [Member] | Development Milestone [Member]                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Revenue Recognition Milestone Method Payments Due $ 5,600,000 € 4.7              
Licensing Agreements [Member] | Columbia License [Member]                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Payment of Upfront Fees     $ 300,000            
Stock Issued During Period, Shares, Issued for Services | shares     1,000,000            
Percentage of common shares issued (in percent)     10.00%            
Licensing Agreements [Member] | Columbia License [Member] | Valuation Technique, Discounted Cash Flow [Member]                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Percentage of lack of marketability       41.70% 41.70%   41.70% 41.70%  
Percentage of weighted average cost of capital       20.50% 20.50%   20.50% 20.50%  
Net of debt in per share | $ / shares       $ 0.021     $ 0.021    
Amount of net of debt utilized       $ 21,000     $ 21,000    
Licensing Agreements [Member] | Columbia License [Member] | Development Milestone [Member]                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Revenue Recognition Milestone Method Payments Due             18,000,000.0    
Licensing Agreements [Member] | Columbia License [Member] | Product milestone                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Revenue Recognition Milestone Method Payments Due             15,300,000    
Licensing Agreements [Member] | Columbia License [Member] | Sale Milestone [Member]                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Revenue Recognition Milestone Method Payments Due             $ 15,000,000.0